Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with Refractory Epilepsy.
Aguirre-Velázquez et al.·Neurology Research International
Klarer NutzenGRADESehr niedrig37 Zitate
Stichproben = 53 Pat.
DauerSeptember 2016
EndpunktAnfallsreduktion
Verblindungn.a.
DesignElterlichen-Survey (Querschnitt, online)
Cannabinoidcbd
Applikationoral
”Kernaussage
Eltern berichteten bei 81,3% der Kinder eine Anfallsreduktion unter Cannabidiol, in 16% vollständige Anfallsfreiheit.
Zusammenfassung
n=53 Kinder (9 Monate – 18 Jahre) mit refraktärer Epilepsie in Mexiko (47% Lennox-Gastaut, 30% unspezifiziert, 19% West-Syndrom); 47,1% hatten zuvor ≥9 Antikonvulsiva erhalten. Elternberichte: 81,3% berichteten Anfallsreduktion unter CBD; moderate bis deutliche Reduktion in 51%, 16% anfallsfrei. Keine schweren Nebenwirkungen; milde UAW (Appetitsteigerung, Schlafveränderungen) in 42%. Unkontrollierte Beobachtungsdaten mit starkem Selektions- und Reporting-Bias.
P
PopulationKinder mit refraktärer Epilepsie (9 Monate bis 18 Jahre), n=53 (davon 43 aus Mexiko); Eltern als Berichterstattende
I
InterventionCannabidiol (medizinisches Cannabis), orale Anwendung, Dosis nicht spezifiziert
O
OutcomeAnfallsreduktion in 81,3% der Fälle; moderate bis signifikante Reduktion in 51%; Anfallsfreiheit in 16%; Reduktion der Antiepileptika-Anzahl in 20,9% der Fälle; milde unerwünschte Wirkungen in 42%
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Sehr niedrig
Niedrigste GRADE-Stufe, die Effektschätzung bleibt unsicher.
Structured online surveys were used to explore the experiences of the parents of children with refractory epilepsy using medicinal cannabis in Mexico during September 2016. The surveys, which were completed in full, were reviewed, and 53 cases of children aged between 9 months and 18 years were identified. Of these, 43 cases (82%) were from Mexico and 10 (18%) were from Latin American countries. Of the 43 Mexican cases, the diagnoses were as follows: 20 cases (47%) had Lennox-Gastaut syndrome (LGS); 13 cases (30%) had unspecified refractory epilepsy (URE); 8 cases (19%) had West syndrome (WS); 1 case (2%) had Doose syndrome (DS); and 1 case (2%) had Ohtahara syndrome (OS). In total, 47.1% of cases had previously been treated with 9 or more anticonvulsant therapies. The parents reported a decrease in convulsions when cannabidiol was used in 81.3% of the cases; a moderate to significant decrease occurred in 51% of cases, and 16% of cases were free from seizure. The number of antiepileptic drugs being used was reduced in 9/43 (20.9%) cases. No serious adverse effects were reported, with only some mild adverse effects, such as increased appetite or changes in sleep patterns, reported in 42% of cases.